Vol. 3 No. 9 (2023)
Reimbursement Reviews

Foslevodopa-Foscarbidopa (Vyalev)

Published September 13, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Foslevodopa-foscarbidopa (Vyalev), 240 mg/mL foslevodopa and 12 mg/mL foscarbidopa solution, subcutaneous infusion.
  • Indication: For the treatment of motor fluctuations in patients with advanced levodopa-responsive Parkinson’s disease who do not have satisfactory control of severe, debilitating motor fluctuations and hyper- /dyskinesia despite optimized treatment with available combinations of Parkinson’s medicinal products.